Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLT Applied Therapeutics	$0.52 +3.5%	$0.41	$0.30 ▼ $10.62	$74.45M	1.97	2.62 million shs	1.56 million shs
COCP Cocrystal Pharma	$1.50 -1.6%	$1.61	$1.12 ▼ $3.26	$15.34M	2.07	42,481 shs	19,511 shs
OVID Ovid Therapeutics	$0.95 +0.4%	$0.49	$0.24 ▼ $1.47	$67.84M	0.2	969,710 shs	691,929 shs
RPTX Repare Therapeutics	$1.56 +1.6%	$1.49	$0.89 ▼ $4.07	$67.02M	0.93	306,303 shs	27,029 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLT Applied Therapeutics	+3.18%	+10.61%	+8.57%	+21.80%	-91.52%
COCP Cocrystal Pharma	-0.65%	-9.52%	-5.59%	+4.11%	-20.42%
OVID Ovid Therapeutics	+1.06%	+10.72%	+56.92%	+231.36%	-15.93%
RPTX Repare Therapeutics	+0.33%	-3.46%	+2.33%	+16.29%	-50.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLT Applied Therapeutics	4.2207 of 5 stars	3.3	3.0	4.7	2.8	1.7	0.6
COCP Cocrystal Pharma	3.0343 of 5 stars	3.5	5.0	0.0	2.7	1.7	0.0
OVID Ovid Therapeutics	4.2441 of 5 stars	3.6	3.0	4.6	2.5	2.5	0.0
RPTX Repare Therapeutics	2.2601 of 5 stars	3.3	3.0	0.0	0.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLT Applied Therapeutics	2.50	Moderate Buy	$6.10	1,079.88% Upside
COCP Cocrystal Pharma	3.00	Buy	$6.00	301.34% Upside
OVID Ovid Therapeutics	3.17	Buy	$3.10	224.95% Upside
RPTX Repare Therapeutics	2.50	Moderate Buy	$4.50	188.46% Upside

Current Analyst Ratings Breakdown

Latest COCP, APLT, OVID, and RPTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	OVID Ovid Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
6/20/2025	COCP Cocrystal Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $6.00
5/27/2025	OVID Ovid Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$2.00 ➝ $1.50

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLT Applied Therapeutics	$460K	161.85	N/A	N/A	$0.12 per share	4.31
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	$0.52 per share	N/A
OVID Ovid Therapeutics	$570K	119.02	N/A	N/A	$0.78 per share	1.22
RPTX Repare Therapeutics	$53.48M	1.25	N/A	N/A	$2.57 per share	0.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLT Applied Therapeutics	-$105.62M	-$0.45	N/A	N/A	N/A	N/A	-354.24%	-144.16%	11/6/2025 (Estimated)
COCP Cocrystal Pharma	-$17.50M	-$1.24	N/A	N/A	N/A	N/A	-144.12%	-102.85%	N/A
OVID Ovid Therapeutics	-$26.43M	-$0.53	N/A	N/A	N/A	-574.44%	-58.87%	-43.18%	N/A
RPTX Repare Therapeutics	-$84.69M	-$2.58	N/A	N/A	N/A	N/A	-78.25%	-66.85%	11/6/2025 (Estimated)

Latest COCP, APLT, OVID, and RPTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	COCP Cocrystal Pharma	-$0.30	-$0.20	+$0.10	-$0.20	N/A	N/A
8/13/2025	Q2 2025	APLT Applied Therapeutics	-$0.17	-$0.15	+$0.02	-$0.15	$0.42 million	N/A
8/13/2025	Q2 2025	OVID Ovid Therapeutics	-$0.16	-$0.06	+$0.10	-$0.06	$0.09 million	$6.27 million
8/8/2025	Q2 2025	RPTX Repare Therapeutics	-$0.56	-$0.39	+$0.17	-$0.39	$2.50 million	$0.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLT Applied Therapeutics	N/A	N/A	N/A	N/A	N/A
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
RPTX Repare Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLT Applied Therapeutics	N/A	1.94	1.94
COCP Cocrystal Pharma	N/A	3.69	4.57
OVID Ovid Therapeutics	0.23	4.72	4.72
RPTX Repare Therapeutics	N/A	6.30	6.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLT Applied Therapeutics	98.31%
COCP Cocrystal Pharma	6.72%
OVID Ovid Therapeutics	72.24%
RPTX Repare Therapeutics	85.09%

Insider Ownership

Company	Insider Ownership
APLT Applied Therapeutics	1.60%
COCP Cocrystal Pharma	28.14%
OVID Ovid Therapeutics	13.10%
RPTX Repare Therapeutics	11.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLT Applied Therapeutics	30	144.01 million	141.71 million	Optionable
COCP Cocrystal Pharma	10	10.26 million	7.37 million	Not Optionable
OVID Ovid Therapeutics	60	71.11 million	61.80 million	Optionable
RPTX Repare Therapeutics	180	42.96 million	38.02 million	Optionable

COCP, APLT, OVID, and RPTX Headlines

Recent News About These Companies

Repare Therapeutics Announces Licensing Deal and Strategic Updates

August 12, 2025 | theglobeandmail.com

Repare Therapeutics (NASDAQ:RPTX) Posts Earnings Results

August 11, 2025 | marketbeat.com

Repare Therapeutics (NASDAQ:RPTX) Upgraded by Wall Street Zen to Hold Rating

August 11, 2025 | americanbankingnews.com

Repare Therapeutics (NASDAQ:RPTX) Stock Rating Upgraded by Wall Street Zen

August 10, 2025 | marketbeat.com

Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates

August 8, 2025 | zacks.com

Repare (RPTX) Q2 Loss Narrows 52%

August 8, 2025 | fool.com

Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

August 8, 2025 | financialpost.comF

Repare Therapeutics (RPTX) to Release Quarterly Earnings on Tuesday

July 30, 2025 | marketbeat.com

ARK Investment Management LLC Sells 875,514 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX)

July 27, 2025 | marketbeat.com

Repare Therapeutics (NASDAQ:RPTX) Trading 0.6% Higher - What's Next?

July 26, 2025 | marketbeat.com

Repare Therapeutics Jumps 15% After $10M Licensing Deal With Debiopharm

July 18, 2025 | uk.finance.yahoo.com

Repare Therapeutics Inc. (RPTX) - Yahoo Finance

July 17, 2025 | finance.yahoo.com

Repare inks licensing deal with Debiopharm for lunresertib

July 16, 2025 | thepharmaletter.comT

Repare finds suitor for paused PKMYT1 inhibitor in current partner Debiopharm

July 16, 2025 | fiercebiotech.comF

Repare Therapeutics Jumps After Hours On $267M Global Licensing Deal With Debiopharm; Retail Traders Rush In

July 16, 2025 | msn.com

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

July 15, 2025 | financialpost.comF

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

July 15, 2025 | financialpost.comF

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

July 15, 2025 | businesswire.com

Repare Therapeutics Inc (RPTX) - Investing.com

July 3, 2025 | investing.com

Repare Therapeutics Inc (RPTX) Stock Forums - Investing.com

June 30, 2025 | investing.com

Repare Therapeutics Out-Licenses Discovery Platforms to DCx Biotherapeutics in Strategic Deal

June 25, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

COCP, APLT, OVID, and RPTX Company Descriptions

Applied Therapeutics NASDAQ:APLT

$0.51 +0.01 (+2.92%)

As of 04:00 PM Eastern

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Cocrystal Pharma NASDAQ:COCP

$1.49 -0.03 (-2.24%)

As of 04:00 PM Eastern

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Ovid Therapeutics NASDAQ:OVID

$0.95 +0.00 (+0.42%)

As of 04:00 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Repare Therapeutics NASDAQ:RPTX

$1.55 +0.02 (+1.04%)

As of 04:00 PM Eastern

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time